However, the prognostic implications of these mutations are often limited, and there is an ongoing debate about the reliability of EGFR, ALK, ROS1, and KRAS for accurately predicting prognosis in NSCLC patients [8,9]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.